https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-25 / Pancreatology 2008;8(4-5):431-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-25 / Pancreatology 2008;8(4-5):431-612008-08-25 00:00:002019-02-15 09:23:41Biological approaches to therapy of pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-22 / Zhonghua Yi Xue Za Zhi 2008 Jul;88(28):1956-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-22 / Zhonghua Yi Xue Za Zhi 2008 Jul;88(28):1956-602008-07-22 00:00:002019-02-15 09:23:40[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-06-01 / Curr Opin Investig Drugs 2008 Jun;9(6):565-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-06-01 / Curr Opin Investig Drugs 2008 Jun;9(6):565-92008-06-01 00:00:002019-02-15 09:23:42Immunotherapy of pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-05-01 / Rev Recent Clin Trials 2008 May;3(2):121-52008-05-01 00:00:002019-02-15 09:23:43Immunotherapy of pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Anticancer Res. 2008 Jan-Feb;28(1B):379-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Anticancer Res. 2008 Jan-Feb;28(1B):379-872008-01-01 00:00:002019-02-15 09:23:44Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Cancer Ther 2008;6(B):955-964
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Cancer Ther 2008;6(B):955-9642008-01-01 00:00:002019-02-15 08:52:42A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-01-01 / Recent Results Cancer Res. 2008;177:165-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-01-01 / Recent Results Cancer Res. 2008;177:165-772008-01-01 00:00:002019-02-15 09:23:44Immunotherapeutic approaches in pancreatic cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-99
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-07-24 / J. Natl. Cancer Inst. 2007 Aug;99(15):1188-992007-07-24 00:00:002020-06-23 09:34:42Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-29 / Gut 2007 Sep;56(9):1275-82
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-29 / Gut 2007 Sep;56(9):1275-822007-03-29 00:00:002019-02-15 09:23:45Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Ai Zheng 2006 Sep;25(9):1082-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Ai Zheng 2006 Sep;25(9):1082-62006-09-01 00:00:002019-02-15 09:23:47[Immunotherapeutic effects of beta-elemene combined with interleukin-23 gene-modified dendritic cells on murine pancreatic carcinoma]
